Johnson & Johnson has submitted for an additional approval for Tremfya (guselkumab) to treat adults with moderately to severely active Crohn's disease. 21 June 2024
In the USA, the Food and Drug Administration has announced the availability of a draft guidance for industry which could smooth the path for biosimilars develop 21 June 2024
Chicagoan biopharma giant AbbVie has picked up a new nod for Skyrizi (risankizumab-rzaa), for adults with moderately to severely active ulcerative colitis. 19 June 2024
British pharma major AstraZeneca has announced that the US Food and Drug Administration has provided a new approval for Imfinzi (durvalumab). 17 June 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.